Total Payments
$221,939
2024 Payments
$38,633
Companies
16
Transactions
216
Medicare Patients
2,321
Medicare Billing
$263,069
Payment Breakdown by Category
Other$192,213 (86.6%)
Travel$17,369 (7.8%)
Food & Beverage$7,053 (3.2%)
Consulting$5,000 (2.3%)
Education$304.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $192,213 | 74 | 86.6% |
| Travel and Lodging | $17,369 | 52 | 7.8% |
| Food and Beverage | $7,053 | 71 | 3.2% |
| Consulting Fee | $5,000 | 6 | 2.3% |
| Education | $304.80 | 13 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $82,807 | 78 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $28,228 | 22 | $0 (2023) |
| Janssen Biotech, Inc. | $27,414 | 22 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $25,651 | 20 | $0 (2017) |
| BeiGene USA, Inc. | $24,801 | 16 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,576 | 23 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $6,856 | 7 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,590 | 3 | $0 (2018) |
| PFIZER INC. | $3,481 | 11 | $0 (2022) |
| Seattle Genetics, Inc. | $1,855 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,633 | 26 | Janssen Biotech, Inc. ($22,866) |
| 2023 | $13,084 | 11 | BeiGene USA, Inc. ($9,034) |
| 2022 | $11,681 | 14 | Incyte Corporation ($9,432) |
| 2021 | $18,573 | 20 | Incyte Corporation ($11,083) |
| 2020 | $13,625 | 16 | AstraZeneca Pharmaceuticals LP ($7,730) |
| 2019 | $45,855 | 49 | Incyte Corporation ($24,836) |
| 2018 | $42,252 | 47 | Incyte Corporation ($19,371) |
| 2017 | $38,236 | 33 | Millennium Pharmaceuticals, Inc. ($25,651) |
All Payment Transactions
216 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $112.65 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $1,096.20 | General |
| Category: Oncology | ||||||
| 08/15/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $121.85 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 07/16/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 07/16/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $123.98 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $89.99 | General |
| Category: Oncology | ||||||
| 07/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $130.96 | General |
| Category: Oncology | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Oncology | ||||||
| 05/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 03/26/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 03/26/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $796.16 | General |
| Category: Oncology | ||||||
| 03/26/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $43.96 | General |
| Category: Oncology | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 02/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 02/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $115.38 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 582 | 961 | $455,842 | $73,809 |
| 2022 | 11 | 604 | 937 | $405,053 | $66,494 |
| 2021 | 9 | 596 | 930 | $383,452 | $69,923 |
| 2020 | 10 | 539 | 931 | $291,448 | $52,843 |
Total Patients
2,321
Total Services
3,759
Medicare Billing
$263,069
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 172 | 371 | $186,242 | $27,371 | 14.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 69 | 110 | $76,890 | $12,473 | 16.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 143 | 196 | $69,384 | $9,512 | 13.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 43 | 43 | $36,636 | $5,861 | 16.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 59 | $23,069 | $5,843 | 25.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 35 | 35 | $22,610 | $3,672 | 16.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 54 | $15,129 | $3,556 | 23.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $11,585 | $2,485 | 21.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 20 | 29 | $3,161 | $1,428 | 45.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 14 | 14 | $6,076 | $900.44 | 14.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 15 | 16 | $3,520 | $412.86 | 11.7% |
| 99447 | Telephone or internet assessment with verbal and written report by consulting physician, 11-20 minutes | Facility | 2023 | 11 | 11 | $1,540 | $294.90 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 180 | 336 | $163,032 | $24,041 | 14.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 159 | 226 | $77,522 | $11,037 | 14.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 102 | $38,419 | $8,531 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 48 | 65 | $43,905 | $7,487 | 17.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $18,457 | $3,322 | 18.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 34 | 55 | $12,689 | $3,221 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 33 | 33 | $20,636 | $3,025 | 14.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 45 | 45 | $18,837 | $2,832 | 15.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 21 | 21 | $7,828 | $1,710 | 21.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 17 | 21 | $2,216 | $991.90 | 44.8% |
| 99447 | Telephone or internet assessment with verbal and written report by consulting physician, 11-20 minutes | Facility | 2022 | 11 | 11 | $1,512 | $296.70 | 19.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 211 | 407 | $174,671 | $31,955 | 18.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 84 | 125 | $70,375 | $14,744 | 21.0% |
About Dr. Paul Kaesberg, M.D
Dr. Paul Kaesberg, M.D is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023084035.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Kaesberg, M.D has received a total of $221,939 in payments from pharmaceutical and medical device companies, with $38,633 received in 2024. These payments were reported across 216 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($192,213).
As a Medicare-enrolled provider, Kaesberg has provided services to 2,321 Medicare beneficiaries, totaling 3,759 services with total Medicare billing of $263,069. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Sacramento, CA
- Active Since 02/28/2006
- Last Updated 08/29/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1023084035
Products in Payments
- JAKAFI (Drug) $67,225
- NINLARO (Drug) $32,240
- OPDIVO (Biological) $27,879
- DARZALEX (Biological) $27,342
- BRUKINSA (Drug) $23,976
- CALQUENCE (Drug) $13,560
- VYXEOS (Drug) $6,856
- ELIQUIS (Drug) $3,380
- ADCETRIS (Biological) $1,855
- SOLIRIS (Drug) $323.11
- Revlimid (Drug) $251.84
- ONUREG (Drug) $124.57
- EMPLICITI (Biological) $103.23
- IBRANCE (Drug) $86.74
- IMBRUVICA (Drug) $71.99
- clonoSEQ (Device) $64.30
- BELEODAQ (Drug) $13.93
- TAZVERIK (Drug) $11.50
- DAURISMO (Drug) $10.70
- BOSULIF (Drug) $3.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Dr. Scott Christensen, M.d, M.D
Hematology & Oncology — Payments: $391,606
Hematology & Oncology $391,606
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Dr. Edward Kim, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $145,977
Hematology & Oncology $145,977